Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462161 · ClinicalTrials.gov registry record · Phase 1
Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02462161 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 24 participants.
The verdict
NCT02462161, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition, daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid deposition in the brain. Participants will be randomly assigned to receive insulin aspart or placebo during a 12-week treatment period.
Interventions
- DRUG Placebo
- DRUG Insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-03-20 |
| Est. Completion | 2019-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462161
The ClinicalTrials.gov registry entry for NCT02462161 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02462161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02462161 about?
NCT02462161 is a clinical study titled "Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart". This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition, daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid deposition in the brain. Participants will be randomly assigned to receive insulin aspart or placebo during a 12-w...
What is the current status of trial NCT02462161?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-03-20. Estimated completion is 2019-04-16.
What interventions are being tested in trial NCT02462161?
The interventions under investigation include: Placebo (DRUG), Insulin aspart (DRUG).
Who is sponsoring clinical trial NCT02462161?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.